Quick Answer
Clearside Biomedical, Inc. reported Stockholders Equity of -$38.86 million for the year ending 2024.
- Clearside Biomedical, Inc. showed a decrease of -144.2% in Stockholders Equity from 2023 to 2024.
- This data is from Clearside Biomedical, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $45.90 million | Q3 2016: $46.94 million | Q1 2017: $67.16 million | Q2 2017: $54.33 million | Q3 2017: $36.90 million | Q1 2018: $85.92 million | Q2 2018: $66.66 million | Q3 2018: $44.08 million | Q1 2019: $16.09 million | Q2 2019: $12.90 million | Q3 2019: $9.76 million | Q1 2020: $10.44 million | Q2 2020: $7.29 million | Q3 2020: $8.12 million | Q1 2021: $16.99 million | Q2 2021: $19.34 million | Q3 2021: $17.85 million | Q1 2022: $31.70 million | Q2 2022: $25.25 million | Q3 2022: $18.55 million | Q1 2023: $2.70 million | Q2 2023: -$4.97 million | Q3 2023: -$12.85 million | Q4 2023: -$15.91 million | Q1 2024: -$21.81 million | Q2 2024: -$28.29 million | Q3 2024: -$34.79 million | Q4 2024: -$38.86 million | Q1 2025: -$45.91 million | Q2 2025: -$48.73 million | Q3 2025: -$53.95 million.
- Over the full 12 years of available data (2013 to 2024), Clearside Biomedical, Inc.'s Stockholders Equity has declined by 261.9%.
- Historical annual values: Fiscal year 2024: -$38.86 million | Fiscal year 2023: -$15.91 million | Fiscal year 2022: $10.61 million | Fiscal year 2021: $37.98 million | Fiscal year 2020: $8.76 million | Fiscal year 2019: $11.16 million | Fiscal year 2018: $23.62 million | Fiscal year 2017: $21.42 million | Fiscal year 2016: $71.66 million | Fiscal year 2015: -$36.66 million | Fiscal year 2014: -$19.21 million | Fiscal year 2013: -$10.74 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: